Analysis of Soluble Interleukin‐2 Receptor as a Prognostic Biomarker in <scp>NMOSD</scp> and <scp>MOGAD</scp>
Serum sIL-2R is elevated in AQP4-IgG+NMOSD and MOGAD and may be a prognostic biomarker for a relapsing disease course in MOGAD.
Authors
- Susanna Asseyer (ORCID: https://orcid.org/0000-0001-6289-1791)
- Philipp Klyscz (ORCID: https://orcid.org/0000-0003-0058-2365)
- Patrick Schindler (ORCID: https://orcid.org/0000-0002-8846-121X)
- Klemens Ruprecht (ORCID: https://orcid.org/0000-0003-1962-6014)
- Judith Bellmann–Strobl (ORCID: https://orcid.org/0000-0003-2615-1643)
- Friedemann Paul (ORCID: https://orcid.org/0000-0002-6378-0070)
- Hannes Ole Tiedt (ORCID: https://orcid.org/0000-0002-8392-1942)
- Christian Meisel
- Carolin Otto (ORCID: https://orcid.org/0000-0002-9768-5143)
Institutions
- Max Delbrück Center (DE)
- Heidelberg University (DE)
- Humboldt-Universität zu Berlin (DE)
- Vivantes Klinikum (DE)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-09-05
- DOI
- https://doi.org/10.1002/acn3.70186
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00